Oncology Central

Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy

0

Natural killer (NK) cells target the cells losing MHC-I in cancer, a phenotype that is similar to certain cells in immune-privileged sites whose milieus are separated from peripheral blood. NK cells are reported to be quantitatively and qualitatively different in immune-privileged sites from those cytotoxic ones in the blood.

To view restricted content, please:
Share:

Leave A Comment